Drug Trial Radar · NCT05572515
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
614
Actual
Start
Mar 29, 2023
Primary completion
Oct 13, 2025
Study completion Aug 31, 2031
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
TeclistamabDrug
Teclistamab will be administered subcutaneously.
PomalidomideDrug
Pomalidomide will be administered orally.
BortezomibDrug
Bortezomib will be administered subcutaneously.
DexamethasoneDrug
Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
CarfilzomibDrug
Carfilzomib will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Progression-free Survival (PFS)Time frame: Up to 9 years
- Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by SeverityTime frame: Up to 9 years
Locations
211 sites in 24 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Banner MD Anderson Cancer Center
Gilbert, Arizona
Alta Bates Comprehensive Cancer Center
Berkeley, California
MemorialCare Long Beach Medical Center
Long Beach, California
University of California Irvine
Orange, California
PIH Health Hospital
Whittier, California
Rocky Mountain Cancer Centers
Aurora, Colorado
University of Connecticut
Farmington, Connecticut
University of Miami Sylvester Cancer Center
Miami, Florida
Orlando Health Cancer Institute
Orlando, Florida
Cleveland Clinic Florida
Weston, Florida
Mission Cancer Blood
Waukee, Iowa
East Jefferson General Hospital Bone Marrow Transport Clinic
Metairie, Louisiana
Walter Reed National Military Medical Center
Bethesda, Maryland
Maryland Oncology Hematology P A
Silver Spring, Maryland
Boston University Medical Center
Boston, Massachusetts
Saint Lukes Hospital Saint Lukes Cancer Specialists
Chesterfield, Missouri
Cooper Health System MD Anderson Cancer Center at Cooper
Camden, New Jersey
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
New York, New York
Durham VAMC
Durham, North Carolina
Penn Medicine Lancaster General Health
Lancaster, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
Brooke Army Medical Center
Fort Sam Houston, Texas
Baylor College of Medicine
Houston, Texas
Michael E DeBakey VA Medical Center
Houston, Texas
Harris Health Smith Clinic
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Alexander T. Augusta Military Medical Center
Fort Belvoir, Virginia
Virginia Oncology Associates
Norfolk, Virginia
NorthWest Medical Specialties, PLLC
Tacoma, Washington
Blacktown Hospital
Blacktown, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Box Hill Hospital
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, Austria
Medical University Vienna MUV
Vienna, Austria
Algemeen Ziekenhuis Klina
Brasschaat, Belgium
Jolimont
Haine-St-Paul, Belgium
Az Groeninge
Kortrijk, Belgium
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.